30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?

Systemic treatment is the standard treatment for unresectable stage III and IV lung cancer. Nevertheless, a 5–10% death rate has been described within 30 days after the last systemic treatment, suggesting that these patient did not benefit. We analysed the 30-day mortality after start of systemic th...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgers, Jacobus Adrianus, Damhuis, Ronald Alphons
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215912/
https://www.ncbi.nlm.nih.gov/pubmed/30406123
http://dx.doi.org/10.1183/23120541.00030-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215912/
https://www.ncbi.nlm.nih.gov/pubmed/30406123
http://dx.doi.org/10.1183/23120541.00030-2018

Ejemplares similares